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Objectives: Primary care practices in England differ in antibiotic prescribing rates, and, anecdotally, prescribers
justify high prescribing rates based on their individual case mix. The aim of this paper was to explore to what ex-
tent factors such as patient comorbidities explain this variation in antibiotic prescribing.
Methods: Primary care consultation and prescribing data recorded in The Health Improvement Network (THIN) data-
base in 2013 were used. Boosted regression trees (BRTs) and negative binomial regression (NBR) models were used
to evaluate associations between predictors and antibiotic prescribing rates. The following variables were considered
as potential predictors: various infection-related consultation rates, proportions of patients with comorbidities, pro-
portion of patients with inhaled/systemic corticosteroids or immunosuppressive drugs, and demographic traits.
Results: The median antibiotic prescribing rate was 65.6 (IQR 57.4–74.0) per 100 registered patients among
348 English practices. In the BRT model, consultation rates had the largest total relative influence on antibiotic
prescribing rate (53.5%), followed by steroid and immunosuppressive drugs (31.6%) and comorbidities (12.2%).
Only 21% of the deviance could be explained by an NBR model considering only comorbidities and age and gen-
der, whereas 57% of the deviance could be explained by the model considering all variables.
Conclusions: The majority of practice-level variation in antibiotic prescribing cannot be explained by variation in
prevalence of comorbidities. Factors such as high consultation rates for respiratory tract infections and high pre-
scribing rates for corticosteroids could explain much of the variation, and as such may be considered in determin-
ing a practice’s potential to reduce prescribing.
Introduction
There is substantial variation in antibiotic prescribing rates be-
tween general practices.1 Part of this variation may be due to med-
ically legitimate reasons, such as differences in the prevalence of
comorbidities or in the age and gender distributions of practices’
catchment populations. For example, English guidelines recom-
mend avoiding antibiotic treatment for self-limiting respiratory
tract infections (RTIs), except if the patient is at high risk of serious
complications because of pre-existing comorbidity.2 Hence, one
would expect higher prescribing rates in practices with a relatively
high number of patients with pre-existing comorbidities compared
with practices with mainly healthy patients without comorbidities.
Similarly, a practice with a high proportion of young children or eld-
erly patients would be expected to have higher prescribing rates
than a practice with mainly working-age adults.1
On the other hand, a substantial fraction of antibiotic prescrip-
tions in primary care are likely to be inappropriate (defined here as
clinically unnecessary).3,4 Variation in the percentage of antibiotics
that are prescribed unnecessarily may also explain part of the
between-practice variation in antibiotic prescribing rates. To date,
it is unclear to what extent observed variation in prescribing be-
tween practices is due to legitimate medical reasons and how
much can be explained by differences in the amount of inappropri-
ate antibiotic prescribing.
In England, to account for differences in the age and gender
profiles of patients that may explain legitimate variation between
practices, comparisons of antibiotic prescribing rates are typically
performed by evaluating antibiotic use per Specific Therapeutic
group Age-sex weighting Related Prescribing Unit (STAR-PU).5–7
In the case of antibiotics, STAR-PU weightings are based on the
number of antibiotic prescriptions in 16 different age and gender
categories (Table 1).6 Using STAR-PU as the denominator instead
of the number of registered patients is intended to result in
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fairer comparisons between practices. However, it is at least ques-
tionable whether it is fair to make comparisons and judge practices
based on STAR-PU while ignoring other differences in case mix.
Patient populations with equal STAR-PU denominators might differ
in the prevalence of comorbidities and consultation rates for vari-
ous infections. These remaining differences might legitimately ex-
plain at least some between-practice variation in antibiotic
prescribing.
In this study, we evaluated the extent to which differences in
comorbidity prevalence, the use of certain drugs, demographics
and consultation rates could explain variation in antibiotic prescrib-
ing, beyond differences already explained by STAR-PU. Better insight
into the importance of these variables in determining antibiotic pre-
scribing rates is needed to better inform policies around inappropri-
ate antibiotic prescribing in primary care.8,9 If variation in antibiotic
prescribing per STAR-PU cannot be explained by differences in the
prevalence of comorbidities or markers of frailty, such as consult-
ation rates, then one can more comfortably set a single prescribing
reduction target for all practices. By contrast, if these factors do play
an important role, one may avoid using the same target for all prac-
tices or develop an alternative way of expressing antibiotic use that
accounts for additional predictors of antibiotic prescribing.
Methods
Ethics
Data from The Health Improvement Network (THIN) were used for this
work. The data collection scheme for THIN is approved by the UK
Multicentre Research Ethics Committee (reference number 07H1102103).
In accordance with this approval, the study protocol was reviewed and
approved by an independent Scientific Review Committee (SRC) (reference
numbers 16THIN071 and 16THIN071-A1).
Data
This cross-sectional study used data from the UK’s THIN, a large primary
care electronic medical record database covering .3.7 million active pa-
tients (7% of the general UK population).10–13 We extracted THIN data
from English practices meeting an acceptable standard for research data
collection and with complete data for the whole period between January
2013 and December 2013.
We identified all systemic antibiotic prescriptions [British National
Formulary chapter 5.1, except antituberculosis drugs (5.1.9) and antileprotic
drugs (5.1.10)14] among permanently registered patients. The number of
patients registered in each gender and age category (Table 1) at each prac-
tice was determined by counting the number of permanently registered pa-
tients in each category of interest at 1 July 2013, thereby assuming a
relatively stable number of patients throughout the year. The number of
STAR-PUs per practice was subsequently estimated by multiplying the num-
ber of patients in each category by the relevant STAR-PU weights.
We considered overall consultation rate as well as consultation rates for
specific conditions, comorbidities, the use of certain prescription drugs and
demographics as potential predictors of antibiotic prescribing rates.
Consultation rates for the following common infection-related conditions
were considered: upper respiratory tract infection (URTI), lower respiratory
tract infection (LRTI), urinary tract infection (UTI), skin condition and acute
otitis media (AOM).1 URTI included sinusitis, common cold/nasopharyngitis,
sore throat, laryngitis/tracheitis and unspecific upper respiratory tract infec-
tions. LRTI included cough, exacerbations of COPD, acute bronchitis, pneu-
monia and unspecific LRTI. UTI included both lower and upper urinary tract
infections. Skin conditions included impetigo, cellulitis, boil/cyst/abscess
and acne. Consultation rates were expressed as the number of consult-
ations per 1000 registered patients.
Relevant comorbidities were based on the Read codes that indicate
high-risk patients who qualify for the free seasonal influenza vaccination
programme.15,16 The Read code classification represents a terminology
used to code primary care electronic health records in the UK.17 The se-
lected comorbidities were asthma, chronic kidney disease, chronic respira-
tory disease, chronic heart disease, diabetes, chronic liver disease,
immunosuppression and chronic neurological disease.15,16 Of these con-
sidered comorbidities, general practice-specific prevalences are publicly
available at the national level for asthma, chronic kidney disease, chronic
respiratory disease, chronic heart disease and diabetes via the Quality
Outcomes Framework (QOF) indicators.18 Ideally one would use a model
with variables that are all also publicly available on a general practice level.
This would facilitate fair comparisons of antibiotic prescribing levels be-
tween practices not captured within THIN, accounting for these publicly
available variables. The proportion of patients with the relevant comorbid-
ities per practice was measured on 1 July 2013.
Besides these comorbidities, we also identified the proportion of pa-
tients within each practice that received at least two prescriptions of one of
the following drugs in the 365 days before 1 July 2013: immunosuppressive
drugs, inhaled corticosteroids and systemic corticosteroids. These drugs are
considered as indicators for patients at risk of complications after (respira-
tory tract) infections.15,16
Statistical analyses
The association between the potential predictor variables listed above and
the number of antibiotic prescriptions per STAR-PU was analysed by general
practice. We used two different methods: a conventional negative binomial
regression (NBR) model19 and a stochastic Poisson boosted regression tree
(BRT) model.20 The number of antibiotic prescriptions was modelled as the
outcome with the natural logarithm of the number of STAR-PUs per practice
as an offset.
Boosted regression trees
An advantage of the BRT model is that it can handle complex non-linear re-
lationships with the outcome—almost all considered predictors were on a
continuous scale—and its results can be intuitively understood, with results
presented as the relative influence of each variable (i.e. predictor) and using
partial dependence plots. The relative importance is a measure based on
the number of times a variable is selected for splitting, weighted by the
squared improvement to the model as a result of each split, and averaged
over all trees.20 The relative importances of all variables included in the
model sum to 100.20–22 The partial dependence plots show the effect of a
Table 1. 2013 Item-based age–sex weighting for oral antibacterials
(British National Formulary, chapter 5.1)
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variable on antibiotic prescribing rate per STAR-PU after accounting for the
average effects of all other variables in the model. For this BRT model, all
potential predictor variables were considered at once.
We used a bagging fraction of 0.5, making the model stochastic, and
fixed the tree complexity to 1, because we were only interested in main ef-
fects and not in interactions between the predictor variables. We ran the
stochastic BRT model 1000 times and averaged results over these runs. All
BRT analyses were performed using the ‘gbm’ and ‘dismo’ packages in R
version 3.2.2.21,22
Negative binomial regression models
We also evaluated associations between the predictor variables listed pre-
viously and the number of antibiotics per STAR-PU using NBR models. We
built six different models, each with a different set of potential predictor
variables. For each model, variables were selected for inclusion in the final
model based on the Akaike information criterion (AIC). For model 1 we did
not consider any potential predictors. For model 2 we considered comorbid-
ities that are captured by the QOF indicators, i.e. asthma, chronic kidney dis-
ease, chronic respiratory disease, chronic heart disease and diabetes, and
demographics (the proportion of patients being male and the proportions
aged ,19 and .64 years).18 For model 3, we additionally considered the
proportion of patients having received at least two prescriptions of im-
munosuppressive drugs, inhaled corticosteroids or systemic corticoster-
oids.23 For model 4, we also considered the proportion of patients with
chronic liver disease, immunosuppressive diseases and chronic neurological
disease (no QOF indicators).
For model 5, we also considered the practice’s consultation rate. Model
6 considered the same variables as model 5, but without any comorbidity.
Comparing countries within the UK
It has been suggested that variation in antibiotic prescribing rates in
England could be mainly explained by geographical location of the practice,
independent of practice and patient population characteristics.24,25
Although we had insufficient data to explore geographical variation within
England, the THIN data allowed us to evaluate whether the country
(England, Scotland, Wales or Northern Ireland) would explain much of the
variation between practices. Since the STAR-PU weighting is based on data
from England only,5 for this analysis we expressed the antibiotic prescribing
rate as the number of antibiotics per mid-year population. The analysis was
performed in the same way as the previously described BRT model, except
that the natural logarithm of the number of registered patients at 1 July
2013 was used as an offset.
Results
In total, 552 practices were included in the analyses. Of these,
348 were located in England, 61 in Wales, 110 in Scotland and
33 in Northern Ireland. For the primary analysis, we focused on
general practices from England. The characteristics of the
348 practices in England are shown in Table 2. There was consider-
able variation in antibiotic prescribing rates, consultation rates and
the percentage of registered patients with relevant comorbidities.
Boosted regression trees
We used BRT to evaluate the relative importance of predictor vari-
ables in explaining between-practice variation in the number of
antibiotic prescriptions per STAR-PU. The relative importance
of each variable is shown in Figure 1. The cross-validation deviance
of the full BRT model was 114.
After averaging over 1000 runs, the variables with the largest
relative influence were URTI consultation rates (18.7%), LRTI con-
sultation rates (18.2%), percentage of patients receiving at least
two prescriptions of systemic steroids (13.7%) and the percentage
of patients receiving at least two prescriptions of inhaled steroids
(12.6%). When summing the relative influences of all consultation
rates, drugs and comorbidities, consultation rates had the largest
total relative influence (49.9%), followed by steroid and immuno-
suppressive drugs (27.6%) and comorbidities (16.8%). The effects
of the six predictor variables with the largest relative influences
were plotted using partial dependence plots (Figure 2). As can be
seen from these plots, the most important variables have a posi-
tive association with the number of antibiotics per STAR-PU.
The skin consultation rates and percentage of patients with liver
disease seem to have a negative association with the number of
antibiotics per STAR-PU.
Negative binomial regression models
We also evaluated associations between the predictor variables
and the number of antibiotics per STAR-PU using NBR models. The
variables included in the final six models and their fit compared
with the null model (model 1) are shown in Table 3. As indicated by
lower AICs and more explained deviance, models 5 and 6 (which
both include consultation rate) provide the best fit to the data. The
small difference in percentage reduction in deviance between
these models indicates that, accounting for other variables, the
importance of comorbidities in explaining differences in antibiotic
prescribing rates per STAR-PU is limited. This is in line with the
Table 2. Characteristics of English general practices included for analysis
Variable Median (IQR)
Antibiotic prescriptions per 100 registered patients 65.6 (57.4–74.0)
Practice size, number of registered patients 7879 (5156–11070)
Patient characteristics
asthma (%) 9.3 (7.7–10.8)
chronic kidney disease (%) 3.9 (2.6–4.9)
diabetes (%) 4.9 (4.1–5.6)
chronic respiratory disease (%) 3.0 (2.1–4.8)
chronic heart disease (%) 4.0 (3.2–4.8)
immunosuppressive disease (%) 0.9 (0.7–1.0)
liver disease (%) 0.2 (0.1–0.2)
neurological disease (%) 2.0 (1.6–2.4)
2 prescriptions of immunosuppressive drugs (%) 0.2 (0.2–0.3)
2 prescriptions of systemic steroids (%) 2.0 (1.4–2.5)
2 prescriptions of inhaled steroids (%) 5.2 (4.6–6.1)
male (%) 49.4 (48.6–50.3)
aged ,18 years (%) 20.2 (18.2–21.8)
aged .64 years (%) 18.2 (14.6–21.8)
URTI consultations/1000 patients 139.0 (111.7–174.1)
LRTI consultations/1000 patients 171.3 (140.7–213.2)
AOM consultations/1000 patients 15.8 (11.2–21.5)
UTI consultations/1000 patients 48.0 (32.2–63.1)
Skin consultations/1000 patients 54.4 (43.8–63.7)
Overall consultations/patient 6.4 (5.3–7.5)
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results of the BRT model, where antibiotic prescribing rates per
STAR-PU were mainly explained by consultation rates and the per-
centage of patients receiving at least two prescriptions of steroids
or immunosuppressive drugs. The BRT model gave similar predic-
tions to the full NBR model (model 5) as shown in Figure 3. While
model 2, allowing publicly available comorbidities and demo-
graphics into the model, explained 17% of the deviance, only 11%
of the deviance was explained by a model considering only publicly
available comorbidities.
Comparing countries within the UK
Noticeable differences in the crude median antibiotic prescribing
rates per 100 registered patients were observed between countries
in the UK: 65.6 (IQR 57.4–74.0) in England; 70.0 (IQR 58.0–79.1) in
Scotland; 77.1 (IQR 68.5–86.5) in Wales; and 90.2 (IQR 76.1–103.9)
in Northern Ireland. Country was an important predictor of antibi-
otic prescribing rates in the BRT model (Figures 4 and 5). Variables
that had an even stronger influence than country were the
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Figure 1. Relative influence of the variables in the model predicting antibiotic prescriptions per STAR-PU in England. Variables are ranked from most
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Figure 2. Partial dependence plots for the six most influential variables in the generalized boosted regression model assessing the association
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percentage of patients receiving at least two prescriptions of
inhaled steroids or systemic steroids and the URTI consultation
rate. The LRTI consultation rate and the percentage of patients
with coronary heart disease were also among the six most influen-
tial predictors (Figure 4).
Discussion
Between-practice variation in age- and gender-weighted antibiotic
prescribing rates could be partly explained by differences in con-
sultation rates for various infectious conditions and the percentage
of patients receiving inhaled and systemic steroids, as well as other
factors to a lesser degree. Although patients with comorbidities
are more likely to receive antibiotics,26 both the BRT model and the
more traditional NBR model indicated that comorbidities had
much lower explanatory power. Even the most extensive NBR
model, considering consultation rates, comorbidities, steroid and
immunosuppressive use and demographics, could not explain
47% of the total deviance, suggesting that a considerable amount
of the between-practice variation is caused by other factors, such
as inappropriate prescribing.3
It is important to consider whether differences in consultation
rates and prescribing rates for inhaled and systemic steroids reflect
legitimate medical reasons for variation in antibiotic prescribing
rates. If they do, policies to reduce prescribing should take into ac-
count these factors. However, if these variables do not represent
legitimate medical reasons for variation in antibiotic prescribing,
they can safely be ignored. Apparent differences in consultation
rates can have several causes.
First, incidences of infection are known to vary by region, partly
due to variation in behavioural, demographic, socioeconomic and
health characteristics of the population in different areas.27–32
Variation in the incidence of infections can be considered as a legit-
imate reason for variation in antibiotic prescribing. Second, differ-
ences in healthcare-seeking behaviour may affect consultation
rates. Some prescribers might attract patients who seek care for
even mild cases of disease. If a proportion of these patients, who
may be less frequently if ever seen in other practices, still receive
an antibiotic because of diagnostic uncertainty and/or to meet pa-
tients’ needs within a short consultation,33,34 higher prescribing
rates would be observed at practices with a patient population
with higher healthcare-seeking behaviour. This type of variation in
healthcare-seeking behaviour may not be considered a legitimate
reason for variation in antibiotic prescribing. In fact, high antibiotic
prescribing rates might actually result in higher consultation rates
and medicalization of self-limiting infections.35,36 Third, differ-
ences in diagnostic coding behaviour might contribute to apparent
differences in consultation rates. It is well known that there is vari-
ation in coding behaviour of practices, with a substantial propor-
tion of visits having either no Read code at all, or only
uninformative Read codes like ‘had a chat with patient’.1,37–39
While overall consultation rates are not influenced by poor coding,
some general practitioners may be more likely to document a
relevant Read code when prescribing an antibiotic. Hence,
infection-related consultation rates may be artificially high in high-
prescribing practices. This type of bias, if present, is clearly not a le-
gitimate reason for variation between antibiotic prescribing rates.
Likewise, differences in the percentage of patients receiving
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underlying causes. First, some practices may truly have a higher
number of severely ill patients that require more systemic and/or
inhaled steroid prescriptions than other practices. Second, higher
use of inhaled and/or systemic steroids may reflect that certain
practices are more liberal with prescribing medication in general,
be it antibiotics or steroids. Among adults presenting in primary
care with sore throat and lower respiratory tract infection, both not
requiring immediate antibiotics, oral corticosteroids appeared to
0 5 10 15 20 25
Diabetes
Chronic respiratory disease
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Upper respiratory tract infection consultations
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Figure 4. Relative influence of the variables in the model predicting antibiotic prescriptions per registered population in the UK. The sum of the























Figure 3. Observed versus expected antibiotic prescriptions per STAR-PU. Each dot represents an individual general practice. The red dots represent
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be ineffective in two recent randomized controlled trials.40,41
Hence, liberal use of corticosteroids to treat respiratory tract infec-
tions does not represent best practice. The first but not the second
of these causes can be considered as a legitimate reason for vary-
ing antibiotic prescribing rates.
This study has several strengths. First, it uses data from a large,
representative sample of UK general practices.11 To our know-
ledge, this is the first study evaluating whether variation in antibi-
otic prescribing rates between general practices can be explained
by differences in consultation rates, the percentage of patients
receiving immunosuppressive drugs, inhaled or systemic steroids,
and the percentage of patients with comorbidities. Moreover, this
is the first study showing substantial differences in antibiotic pre-
scribing rates between countries within the UK. We used two dif-
ferent methodologies: boosted regression trees20 and negative
binomial regression19 Both resulted in similar conclusions, thereby
strengthening confidence in our results.
This study has also some limitations. As described above, some
of the predictor variables may be markers of both legitimate as
well as non-legitimate reasons for variation in antibiotic prescribing
rates. In addition, variation in prescribing may be further explained
by factors that were not readily available to us, such as markers of
the severity of infections.42–45 We analysed only antibiotic items
prescribed by the practice, which may artificially create differences
between practices that tend to prescribe multiple shorter courses
compared with practices that tend to prescribe one longer course
for the same condition. Finally, ideally one would obtain a parsimo-
nious model with a good fit using only variables that are publicly
available for all practices. Although between-practice variations in
prescribing of inhaled and systemic steroids are readily available to
identify practices that may legitimately have higher prescribing
rates per STAR-PU—if assumed to be markers of more severely ill
patients—this is unfortunately not possible for consultation rates
using publicly available data.
Conclusions
The proportion of patients with comorbidities in a practice’s patient
population does not explain a substantial proportion of the vari-
ance in antibiotic prescribing rates, suggesting that practice-level
prescribing targets do not necessarily have to take into account
the different levels of comorbidities.
Although we cannot exclude the possibility that consultation
rates and use of inhaled and systemic steroids may be markers of
(i) poor coding practice, (ii) a high propensity to prescribe drugs in
general, or (iii) stronger health-care seeking behaviour, the predict-
ive power of these variables indicates that one should be careful in
setting the same practice-level antibiotic prescribing target for all
practices, and that differences in these variables between prac-
tices may need to be taken into account. Further studies are
needed to evaluate whether the explanatory power of consult-
ation rates is mainly due to true differences in the incidence of in-
fection or severity of infections, or e.g. due to differences in
healthcare-seeking behaviour.
Acknowledgements
The authors are grateful for the support of a group of subject matter ex-
perts who formed a Modelling Oversight Group (MOG) that convened bi-
monthly to discuss and review this work. Group members are listed in
another paper of this supplement.3 J. V. R. is affiliated with the National
Institute for Health Research Health Protection Research Units (NIHR HPRU)
in Healthcare Associated Infection and Antimicrobial Resistance at both
Imperial College London and University of Oxford in partnership with PHE.
Funding
This paper was published as part of a Supplement supported and
resourced by Public Health England (PHE). Only internal resources were































































































































2 4 6 8 10 0 100 200 300 400 500 1 2 3
Systemic steroids (%)
4 5
Inhaled steroids (%) URTI consultations per 1000 patients
E NI S W 0 100 200 300 2 4 6 8
Coronary heart disease (%)
400
LRTI consultations per 1000 patientsCountry
Figure 5. Partial dependence plots for the six most influential variables in the generalized boosted regression model assessing the association be-
tween predictors and antibiotic prescribing rates per registered population in the UK. The y-axes are centred to have zero mean over the data distribu-
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